Viking Ther­a­peu­tics plans Ph2 tri­al for oral obe­si­ty drug af­ter pos­i­tive ear­ly-stage da­ta

Viking Ther­a­peu­tics tout­ed ear­ly-stage obe­si­ty da­ta show­ing its oral GLP-1/GIP dual ag­o­nist pro­duced 5.3% weight loss and few side ef­fects, send­ing the com­pa­ny’s stock $VK­TX soar­ing about 23% on Tues­day morn­ing.

Viking’s once-dai­ly drug, dubbed VK2735, demon­strat­ed up to a 5.3% re­duc­tion in body weight from base­line in healthy pa­tients af­ter 28 days. Up to 57% of par­tic­i­pants who took VK2735 lost at least 5% of their body weight.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER